FAPI-PEG3-K-TPP: Mitochondria-Targeted Radioconjugate for Enhanced Tumor Retention

Guoyu Wang published this dataset on figshare in March 2026. It contains data on a novel fibroblast activation protein inhibitor (FAPI) derivative designed for sequential targeting and radiopharmaceutical therapy. The dataset includes results for the agent radiolabeled with 68Ga and 177Lu, showing high radiochemical purity and yield exceeding 95%.

Use Cases

• Compare tumor uptake and retention times between FAPI-PEG3-K-TPP and FAPI-46 based on in vivo SPECT study results.
• Analyze the relationship between mitochondrial targeting and tumor growth suppression based on data from the 177Lu-labeled complex.
• Evaluate radiochemical purity and stability metrics for the novel FAPI derivative described in the study.

Strengths

• Dataset includes specific performance metrics, such as radiochemical purity and yield exceeding 95%.
• In vivo results show a dramatic increase in tumor retention time, exceeding 120 hours compared to less than 48 hours for FAPI-46.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.

Provenance

Source

Guoyu Wang via figshare

Collection Method

Likely contains experimental results from the synthesis and evaluation of the FAPI-PEG3-K-TPP radioconjugate.

Freshness

Last updated 2026-03-18 19:41:44; freshness should be verified.